|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Enokida H, Yoshino H, Matsushita R and
Nakagawa M: The role of microRNAs in bladder cancer. Investig Clin
Urol. 57 (Suppl 1):S60–S76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kaufman DS, Shipley WU and Feldman AS:
Bladder cancer. Lancet. 374:239–249. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rose TL and Milowsky MI: Improving
systemic chemotherapy for bladder cancer. Curr Oncol Rep.
18:272016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen K and Rajewsky N: The evolution of
gene regulation by transcription factors and microRNAs. Nat Rev
Genet. 8:93–103. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smits M, Nilsson J, Mir SE, van der Stoop
PM, Hulleman E, Niers JM, de Witt Hamer PC, Marquez VE, Cloos J,
Krichevsky AM, et al: miR-101 is down-regulated in glioblastoma
resulting in EZH2-induced proliferation, migration, and
angiogenesis. Oncotarget. 1:710–720. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Malizia AP and Wang DZ: MicroRNAs in
cardiomyocyte development. Wiley Interdiscip Rev Syst Biol Med.
3:183–190. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Taft RJ, Pang KC, Mercer TR, Dinger M and
Mattick JS: Non-coding RNAs: Regulators of disease. J Pathol.
220:126–139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Schooneveld E, Wildiers H, Vergote I,
Vermeulen PB, Dirix LY and Van Laere SJ: Dysregulation of microRNAs
in breast cancer and their potential role as prognostic and
predictive biomarkers in patient management. Breast Cancer Res.
17:212015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng L, Yang T, Kuang Y, Kong B, Yu S,
Shu H, Zhou H and Gu J: MicroRNA-23a promotes neuroblastoma cell
metastasis by targeting CDH1. Oncol Lett. 7:839–845. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pan Y, Li J, Zhang Y, Wang N, Liang H, Liu
Y, Zhang CY, Zen K and Gu H: Slug-upregulated miR-221 promotes
breast cancer progression through suppressing E-cadherin
expression. Sci Rep. 6:257982016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liang Z, Li X, Liu S, Li C, Wang X and
Xing J: MiR-141-3p inhibits cell proliferation, migration and
invasion by targeting TRAF5 in colorectal cancer. Biochem Biophys
Res Commun. 514:699–705. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schoolmeesters A, Eklund T, Leake D,
Vermeulen A, Smith Q, Force Aldred S and Fedorov Y: Functional
profiling reveals critical role for miRNA in differentiation of
human mesenchymal stem cells. PLoS One. 4:e56052009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheung TH, Quach NL, Charville GW, Liu L,
Park L, Edalati A, Yoo B, Hoang P and Rando TA: Maintenance of
muscle stem-cell quiescence by microRNA-489. Nature. 482:524–528.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dang X, Ma A, Yang L, Hu H, Zhu B, Shang
D, Chen T and Luo Y: MicroRNA-26a regulates tumorigenic properties
of EZH2 in human lung carcinoma cells. Cancer Genet. 205:113–123.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mayr C, Hemann MT and Bartel DP:
Disrupting the pairing between let-7 and Hmga2 enhances oncogenic
transformation. Science. 315:1576–1579. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang B, Ji S, Ma F, Ma Q, Lu X and Chen
X: miR-489 acts as a tumor suppressor in human gastric cancer by
targeting PROX1. Am J Cancer Res. 6:2021–2030. 2016.PubMed/NCBI
|
|
20
|
Yuan P, He XH, Rong YF, Cao J, Li Y, Hu
YP, Liu Y, Li D, Lou W and Liu MF: KRAS/NF-κB/YY1/miR-489 signaling
axis controls pancreatic cancer metastasis. Cancer Res. 77:100–111.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gao S, Liu H, Hou S, Wu L, Yang Z, Shen J,
Zhou L, Zheng SS and Jiang B: miR-489 suppresses tumor growth and
invasion by targeting HDAC7 in colorectal cancer. Clin Transl
Oncol. 20:703–712. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cui X, Kong C, Zhu Y, Zeng Y, Zhang Z, Liu
X, Zhan B, Piao C and Jiang Z: miR-130b, an onco-miRNA in bladder
cancer, is directly regulated by NF-κB and sustains NF-κB
activation by decreasing cylindromatosis expression. Oncotarget.
7:48547–48561. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bollag G, Hirth P, Tsai J, Zhang J,
Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al:
Clinical efficacy of a RAF inhibitor needs broad target blockade in
BRAF-mutant melanoma. Nature. 467:596–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Qu W, Jiang Y, Sun Y, Cheng Y, Zou T
and Du S: miR-489 suppresses proliferation and invasion of human
bladder cancer cells. Oncol Res. 24:391–398. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soni M, Patel Y, Markoutsa E, Jie C, Liu
S, Xu P and Chen H: Autophagy, cell viability, and chemoresistance
are regulated by miR-489 in breast cancer. Mol Cancer Res.
16:1348–1360. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wu H, Xiao Z, Zhang H, Wang K, Liu W and
Hao Q: MiR-489 modulates cisplatin resistance in human ovarian
cancer cells by targeting Akt3. Anticancer Drugs. 25:799–809. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xie Z, Cai L, Li R, Zheng J, Wu H, Yang X,
Li H and Wang Z: Down-regulation of miR-489 contributes into NSCLC
cell invasion through targeting SUZ12. Tumour Biol. 36:6497–6505.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu Q, Yang G and Qian Y: Loss of
MicroRNA-489-3p promotes osteosarcoma metastasis by activating
PAX3-MET pathway. Mol Carcinog. 56:1312–1321. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Thurn KT, Thomas S, Raha P, Qureshi I and
Munster PN: Histone deacetylase regulation of ATM-mediated DNA
damage signaling. Mol Cancer Ther. 12:2078–2087. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang W, Zhou W, Xiang L, Wu X, Zhang P,
Wang J, Liu G, Zhang W, Peng Y, Huang X, et al: The
p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell
proliferation in human colorectal cancer. Nat Commun. 10:6632019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li S, Wang F, Qu Y, Chen X, Gao M, Yang J,
Zhang D, Zhang N, Li W and Liu H: HDAC2 regulates cell
proliferation, cell cycle progression and cell apoptosis in
esophageal squamous cell carcinoma EC9706 cells. Oncol Lett.
13:403–409. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krämer OH: HDAC2: A critical factor in
health and disease. Trends Pharmacol Sci. 30:647–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi TP, Xu H, Wei JF, Ai X, Ma X, Wang BJ,
Ju ZH, Zhang GX, Wang C, Wu ZQ and Zhang X: Association of low
expression of notch-1 and jagged-1 in human papillary bladder
cancer and shorter survival. J Urol. 180:361–366. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Orenay-Boyacioglu S, Kasap E, Gerceker E,
Yuceyar H, Demirci U, Bilgic F and Korkmaz M: Expression profiles
of histone modification genes in gastric cancer progression. Mol
Biol Rep. 45:2275–2282. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jin KL, Pak JH, Park JY, Choi WH, Lee JY,
Kim JH and Nam JH: Expression profile of histone deacetylases 1, 2
and 3 in ovarian cancer tissues. J Gynecol Oncol. 19:185–190. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shan W, Jiang Y, Yu H, Huang Q, Liu L, Guo
X, Li L, Mi Q, Zhang K and Yang Z: HDAC2 overexpression correlates
with aggressive clinicopathological features and DNA-damage
response pathway of breast cancer. Am J Cancer Res. 7:1213–1226.
2017.PubMed/NCBI
|
|
38
|
Niegisch G, Knievel J, Koch A, Hader C,
Fischer U, Albers P and Schulz WA: Changes in histone deacetylase
(HDAC) expression patterns and activity of HDAC inhibitors in
urothelial cancers. Urol Oncol. 31:1770–1779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pinkerneil M, Hoffmann MJ, Deenen R,
Köhrer K, Arent T, Schulz WA and Niegisch G: Inhibition of class I
histone deacetylases 1 and 2 promotes urothelial carcinoma cell
death by various mechanisms. Mol Cancer Ther. 15:299–312. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
La Noce M, Paino F, Mele L, Papaccio G,
Regad T, Lombardi A, Papaccio F, Desiderio V and Tirino V: HDAC2
depletion promotes osteosarcoma's stemness both in vitro and in
vivo: A study on a putative new target for CSCs directed therapy. J
Exp Clin Cancer Res. 37:2962018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sun D, Yu M, Li Y, Xing H, Gao Y, Huang Z,
Hao W, Lu K, Kong C, Shimozato O, et al: Histone deacetylase 2 is
involved in DNA damage-mediated cell death of human osteosarcoma
cells through stimulation of the ATM/p53 pathway. FEBS Open Bio.
9:478–489. 2019. View Article : Google Scholar : PubMed/NCBI
|
